Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. CELC.NASDAQ

Celcuity LLC (CELC NASDAQ) stock market data APIs

$19.41 0.68(3.6%) as of July 26, 2024
Price chart is built with Anychart

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Celcuity LLC Financial Data Overview

18.73
19.41
-
19.77
18.6
8.389-22.188
672 M
35 101 K
0
-0.64
0.805
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CELC',
Type: 'Common Stock',
Name: 'Celcuity LLC',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00HKBW045',
ISIN: NULL,
CUSIP: NULL,
CIK: '1603454',
EmployerIdNumber: '82-2863566',
FiscalYearEnd: 'December',
IPODate: '2017-09-20',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Celcuity LLC Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -76 048 240
  • Earnings Per Share -2.85
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Celcuity LLC Earnings via APIs

  • Latest Release 2024-05-15
  • EPS/Forecast -0.71

Get Celcuity LLC End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Celcuity LLC latest news via APIs

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its parti...
  • BREAST CANCER
  • CALENDAR OF EVENTS
  • CELCUITY INC
  • CONFERENCES
  • GEDATOLISIB
  • NASDAQ:CELC
  • PHARMA
  • PROSTATE CANCER
  • VIKTORIA-1

Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a clinical trial collabora...
  • BREAST CANCER
  • CALENDAR OF EVENTS
  • CELCUITY INC
  • CONFERENCE CALLS/ WEBCASTS
  • EARNINGS RELEASES AND OPERATING RESULTS
  • FINANCIAL RESULTS
  • GEDATOLISIB
  • NASDAQ:CELC
  • PHARMA
  • PROSTATE CANCER
  • VIKTORIA-1
Do you have any questions?
support@eodhistoricaldata.com